Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-07-17

Clinical Trial Update: Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating dasatinib in locally advanced triple-negative breast cancer was terminated, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • DASATINIB (Dasatinib)

Snippet

Sponsor: Baylor Breast Care Center | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2012-07-17